Regeneron Pharmaceuticals' Change in Accured Expenses fell 11094.86% to -$24.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $736.8 million, marking a year-over-year increase of 23.13%. This contributed to the annual value of $736.8 million for FY2025, which is 23.13% up from last year.
Per Regeneron Pharmaceuticals' latest filing, its Change in Accured Expenses stood at -$24.7 million for Q4 2025, which was down 11094.86% from $759.2 million recorded in Q3 2025.
Regeneron Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $759.2 million during Q3 2025, with a 5-year trough of -$250.4 million in Q1 2022.
Over the past 5 years, Regeneron Pharmaceuticals' median Change in Accured Expenses value was $114.8 million (recorded in 2023), while the average stood at $139.9 million.
Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 85984.25% in 2021, then plummeted by 62161.38% in 2022.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Change in Accured Expenses stood at $365.7 million in 2021, then fell by 4.95% to $347.6 million in 2022, then crashed by 139.9% to -$138.7 million in 2023, then surged by 262.65% to $225.6 million in 2024, then crashed by 110.95% to -$24.7 million in 2025.
Its Change in Accured Expenses stands at -$24.7 million for Q4 2025, versus $759.2 million for Q3 2025 and $216.4 million for Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value